A nanotherapeutic strategy to target drug-tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
Cancer Commun (Lond)
.
2023 Jan 24.
doi: 10.1002/cac2.12401.
Online ahead of print.
Authors
Tatiana Shaurova
1
,
Lingyue Yan
2
,
Yafei Su
2
,
Laurie James Rich
3
4
,
Vui King Vincent-Chong
5
,
Hannah Calkins
1
,
Saraswati Pokharel
6
,
Martin Petkovich
7
,
Mukund Seshadri
5
,
Yun Wu
2
,
Pamela Anne Hershberger
1
Affiliations
1
Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
2
Department of Biomedical Engineering, University at Buffalo, the State University of New York, Buffalo, New York, USA.
3
Cell Stress and Biophysical Oncology Graduate Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
4
Fujifilm-VisualSonics Corporation, Toronto, Ontario, Canada.
5
Department of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
6
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
7
Cancer Research Institute, School of Medicine, Queens University, Kingston, Ontario, Canada.
PMID:
36691995
DOI:
10.1002/cac2.12401
No abstract available
Publication types
Letter